DG
ALXN

Delek Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Delek Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$21.5M Buy
167,933
+25,000
+17% +$3.22M 0.83% 44
2019
Q1 		$19.2M Sell
142,933
-19,000
-12% -$2.36M 0.8% 48
2018
Q4 		$16.2M Buy
161,933
+37,755
+30% +$4.46M 0.74% 45
2018
Q3 		$17.2M Sell
124,178
-10,000
-7% -$1.25M 0.72% 44
2018
Q2 		$16.7M Buy
134,178
+30,000
+29% +$3.51M 0.71% 43
2018
Q1 		$11.6M Buy
104,178
+18,000
+21% +$2.15M 0.6% 60
2017
Q4 		$10.3M Buy
+86,178
New +$10.5M 0.55% 62

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Delek Group's ALXN Position: Q2 2019 in Review

Delek Group increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q2 2019, buying an estimated $3.22M and bringing the position to 167,933 shares worth $21.5M. The position accounts for 0.83% of the portfolio, ranked #44.

Delek Group first reported a position in ALXN in Q4 2017 and has held it in 7 quarters since. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Delek Group held 167,933 shares of Alexion Pharmaceuticals worth $21.5M as of Q2 2019.
  • Delek Group bought 25,000 Alexion Pharmaceuticals shares in Q2 2019, an estimated $3.22M.
  • Alexion Pharmaceuticals made up 0.83% of Delek Group's portfolio in Q2 2019, its #44 holding.
  • Delek Group first reported a position in Alexion Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Delek Group's 13F filing for Q2 2019, filed 8 Aug 2019.